Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Receivables (2019 - 2025)

Biodesix (BDSX) has disclosed Receivables for 7 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 5.03% year-over-year to $9.0 million, compared with a TTM value of $9.0 million through Dec 2025, up 5.03%, and an annual FY2025 reading of $9.0 million, up 5.03% over the prior year.
  • Receivables was $9.0 million for Q4 2025 at Biodesix, down from $12.7 million in the prior quarter.
  • Across five years, Receivables topped out at $18.4 million in Q1 2021 and bottomed at $2.8 million in Q3 2021.
  • Average Receivables over 5 years is $7.2 million, with a median of $6.6 million recorded in 2023.
  • The sharpest move saw Receivables crashed 79.45% in 2022, then soared 145.88% in 2024.
  • Year by year, Receivables stood at $3.7 million in 2021, then soared by 38.54% to $5.1 million in 2022, then skyrocketed by 51.61% to $7.7 million in 2023, then increased by 12.03% to $8.6 million in 2024, then rose by 5.03% to $9.0 million in 2025.
  • Business Quant data shows Receivables for BDSX at $9.0 million in Q4 2025, $12.7 million in Q3 2025, and $7.5 million in Q2 2025.